more_reports

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

TICKERS: GREY; AGNPF; AGW2

Alzheimer's Brain Scan Clinic Clears Major Medicare Hurdle

View Important Disclosures for this Article

Source:

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) secured accreditation and completed Medicare and Medicaid enrollment for its flagship brain PET imaging clinic in Florida.

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) announced on November 16 that its flagship NovaScan Neuroimaging Clinics location in Davie, Florida, had received accreditation and completed enrollment in both U.S. Medicare and Medicaid programs. The development allows the clinic to provide diagnostic imaging services to eligible patients enrolled in those programs, with established billing codes for brain positron emission tomography (PET) scans and the radioactive isotopes used in the procedures.

The inaugural clinic is located in the HCA Florida University Medical Office Building on the campus of HCA Florida University Hospital. According to Grey Matters, it is the first facility of its kind in the United States dedicated to providing brain-specific PET scans to assist in detecting Alzheimer's disease and other neurodegenerative conditions.

Diagnostic imaging centers in the United States must obtain accreditation from one of four governing bodies to fully enroll in Medicare, receive payments through the program, and negotiate in-network contracts with most private insurers. Grey Matters stated that completing accreditation and enrollment established access to its Davie clinic's services for eligible Medicare and Medicaid beneficiaries.

The accreditation process evaluates several clinical requirements, including radiation dose control, diagnostic imaging accuracy, and staff qualifications. Reviews cover scanning protocols, equipment calibration, and sample clinical images to assess imaging quality and reduce unnecessary radiation exposure or repeat scans. The process also verifies that radiologists, medical physicists, and technologists maintain appropriate licenses, certifications, and continuing training.

NovaScan locations are designed around the U.S. Food and Drug Administration-cleared CareMiBrain PET brain scanning system. The chair-style equipment produces brain images without an integrated computed tomography (CT) component, which the company said results in 25% less radiation exposure for patients. Grey Matters also reported that brain PET scans used to detect beta-amyloid plaques associated with Alzheimer's disease are covered by Medicare, Medicaid, and most private insurance plans for patients aged 65 and older.

"We have now reached the point in our commercialization pathway where we can begin introducing doctors and patients to the many features of our new clinic, including our brain-dedicated PET scan technology," said Christopher J. Moreau, CEO of Grey Matters Health Inc., in the company's news release.

Moreau also identified advanced image resolution, earlier diagnosis of neurodegenerative diseases and an enhanced patient experience as elements of Grey Matters' approach to establishing a network of dedicated brain PET imaging clinics in the United States.

First Patient Scans and Additional Florida Locations

Grey Matters identified the beginning of patient examinations at its Davie facility as an operational milestone. Its first FDA-cleared CareMiBrain scanner was delivered in July 2026, and the company received its Florida Radioactive Materials License on August 20.

The Davie clinic occupies approximately 2,200 square feet and is designed to operate with two on-site staff members, while radiology interpretations are performed remotely. Grey Matters appointed Dr. Jayson A. Lord as medical director. Its October 13 investor presentation described Lord as a board-certified diagnostic radiologist with 25 years of experience and licenses in 12 U.S. states, including Florida.

Establishing physician referrals is another component of the initial operating process.

In a November 5 Streetwise Reports article, Moreau discussed the need for referring physicians to become familiar with NovaScan's services as the first clinic establishes patient volumes.

"Physicians have to get used to us; they've got to hear about us," Moreau said.

Technical analyst Stewart Thomson assigned Grey Matters a "Speculative Buy" technical rating.1

Grey Matters has stated that patients must receive physician referrals rather than visit NovaScan clinics for walk-in screening. Under an arrangement with ProScan Reading Services, subspecialty radiologists perform interpretations remotely, while the company intends to provide referring physicians with access to patient images. Moreau identified a target turnaround of 24 to 48 hours for returning reports.

Beyond Davie, Grey Matters has identified Tampa, Florida, as a possible location for a second NovaScan clinic. It previously signed a non-binding letter of intent involving a minimum of 200 PET scans for an Alzheimer's clinical trial at a proposed second facility. The arrangement remains preliminary, with no definitive services agreement, confirmed scanning schedule, or clinical-trial revenue established.

Management has also discussed establishing an initial cluster of three or four clinics in Florida. Moreau identified Miami and The Villages among the potential markets under consideration, although neither location was presented as finalized.

Plans for a National Neuroimaging Network

Grey Matters outlined a broader U.S. development strategy in its October 13 investor presentation, identifying a planned network of 100 NovaScan Neuroimaging Clinics locations. The proposed facilities would focus on brain-specific PET imaging for Alzheimer's disease, with additional areas of interest including frontotemporal dementia and Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications 

In later discussions with Streetwise Reports, the company described longer-term expansion plans involving up to 200 U.S. locations. Moreau also identified a goal of establishing at least 100 clinics within two to two-and-a-half years. These figures represent the expansion objectives described in the respective company materials and interviews.

Grey Matters intends to use existing medical-office space when establishing facilities, rather than construct locations around larger conventional PET/CT systems. Management has discussed developing a process through which additional clinics could be established in approximately 90 to 120 days.

The initial Florida locations are also part of the process for determining which administrative and operational functions would remain at individual clinics and which could be managed centrally. Moreau has discussed preparing several locations simultaneously as Grey Matters develops its operating procedures.

Under the proposed corporate structure, Grey Matters would operate through a wholly owned holding company subsidiary with direct ownership of NovaScan independent diagnostic testing facilities. In states requiring physician-owned professional corporations to own medical clinics, the company described an arrangement under which it would provide management services through agreements with those corporations.

The NovaScan network is designed around the CareMiBrain PET Brain Scanning System, which received FDA clearance in 2024 and holds a CE Mark for Europe. According to Grey Matters, the proposed NovaScan locations would use the first CareMiBrain systems purchased for operation in the United States.

The system weighs approximately 662 pounds and operates using standard 115-240V electrical power. Its compact, chair-based configuration is designed for brain imaging without the CT component incorporated into conventional PET/CT systems.

The October presentation listed an equipment cost of approximately US$850,000 for CareMiBrain, compared with estimated conventional PET/CT equipment costs ranging from US$3 million to US$5 million. Grey Matters also identified differences in installation requirements, equipment weight, and structural accommodations between the systems.

The company's imaging strategy incorporates developments in Alzheimer's treatment. Two FDA-approved monoclonal antibody therapies, Leqembi from Eisai and Biogen and Kisunla from Eli Lilly, target beta-amyloid plaques associated with the disease. Both treatments require confirmation of amyloid pathology before administration, which can involve PET imaging or other approved testing methods.

Kisunla also uses follow-up PET imaging to assess amyloid plaque reduction and help determine when treatment can stop. The November 5 Streetwise Reports article examined this distinction between initial diagnostic imaging and subsequent examinations used to assess treatment response.

In October 2023, the Centers for Medicare & Medicaid Services removed its previous once-per-lifetime restriction on amyloid PET scans. Coverage decisions are now handled by local Medicare Administrative Contractors under applicable requirements, rather than through the former national lifetime limit.

Grey Matters' October presentation also identified repeat scans as part of monitoring Alzheimer's therapies. It listed Leqembi as a twice-monthly infusion treatment with an annual cost of US$26,500 and Kisunla as a monthly infusion treatment with an annual cost of US$32,000, with Medicare, Medicaid and private insurance coverage described for eligible patients.

Clinic Economics and Operating Capacity

Grey Matters' October investor presentation established a standard clinic footprint of approximately 1,500 to 1,750 square feet and identified capital requirements of US$1.1 million per location, assuming a fully built-out space.

The model allocated US$850,000 to the PET scanner, with 80% financing assumed, and US$250,000 to shielding, furniture, clinic equipment and supplies, marketing and working capital. In subsequent comments, Moreau said he believed 100% financing of the brain PET scanner system would become available in the near future.

Grey Matters estimated monthly operating costs of US$65,000 for a clinic staffed by two employees covering nuclear medicine technology and reception administration. The presentation identified a maximum scanning capacity of 15 procedures per day and 3,600 annually, with a calculated break-even point of only 1.6 scans per day.

Referral Development and Commercial Partnerships

Grey Matters outlined a patient acquisition strategy focused on medical specialists, primary care physicians, the general public, and contract research organizations.

The company will be targeting neurologists, geriatricians, psychiatrists, and primary care physicians. with its marketing, communications, and awareness programs.

The presentation identified 131,434 practicing U.S. professionals within its specialist referral category, 260,687 practicing primary care physicians, and 104.7 million Americans between ages 45 and 65. It also referenced 162 Alzheimer's disease drugs under development in discussing contract research organizations and identified Biogen and Lilly as primary care market expansion allies.

Grey Matters identified Catalyst MedTech as a launch partner for the NovaScan network. Catalyst serves as the exclusive U.S. distributor of the CareMiBrain brain-specific PET scanner and has approximately 500 employees with a nationwide presence.

The October presentation reported that Catalyst entered into a US$4 million supply, financing, and services agreement with Algernon Health, the entity named in the presentation. Associated services included radioactive materials application consultation, preparation of licensing documentation, assistance with regulatory submissions, and support for clinical policies and procedures.

ProScan Reading Services was identified as another launch partner. The physician-owned and managed teleradiology company provides remote imaging interpretation services to approximately 500 medical centers, hospitals, and imaging clinics worldwide. Its arrangement with Grey Matters supplies the radiology interpretation component of the NovaScan operating model.

GE HealthCare Technologies was also identified as a launch ally. GE HealthCare distributes Vizamyl F18-PET tracers, also known as flutemetamol F-18, which target beta-amyloid plaques and were identified for use in the proposed clinics.

According to the presentation, GE HealthCare's marketing team would help introduce NovaScan to neurologists, geriatricians and psychiatrists in new markets and participate in insurance preauthorization activities.

The November 5 article also identified radiotracer delivery distances and availability as considerations in selecting future clinic locations, given the limited usable lifetime of radioactive imaging materials.

Grey Matters completed a CA$1.25 million private placement in June 2026 to support development of its first U.S. clinic. Another financing, announced on August 20, 2026, was subsequently completed.

The first tranche of that offering closed on September 10 and generated CA$600,000. A second and final tranche closed on September 23, raising an additional CA$520,000 and bringing total gross proceeds to CA$1.12 million.

The second tranche included CA$270,000 from the sale of 675,000 equity units at CA$0.40 each and CA$250,000 from unsecured convertible debenture units. Across both tranches, the completed offering included CA$555,000 in equity proceeds and CA$565,000 from convertible debenture units.

According to Grey Matters, proceeds were intended to advance its Alzheimer's disease program toward the opening of a U.S. brain-specific neuroimaging clinic, support general and administrative expenses, and provide working capital.

Outside the NovaScan business, Grey Matters maintains drug-development interests that include Repirinast (NP-251) for chronic kidney disease and a proprietary DMT program focused on recovery from stroke and traumatic brain injury. It also holds a 20% equity interest in Seyltx, which is developing Ifenprodil for chronic cough.

Technical Analyst Identifies 'Buy' Signals Following Regulatory Milestone

1In a September 10, 2026, report titled "Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone," technical analyst Stewart Thomson reviewed Grey Matters Health following its receipt of a Florida Radioactive Materials License and progress toward establishing its first U.S. brain PET imaging clinic.

Thomson assigned Grey Matters a "Speculative Buy" technical rating and identified short-term, medium-term, and long-term resistance levels of CA$0.85, CA$1.20, and CA$1.65, respectively.

His assessment focused on trading patterns and momentum indicators, including a bull wedge formation accompanied by increased volume near the base of the pattern. Thomson reported a crossover "Buy" signal from the Stochastics oscillator, rising Money Flow Index and On-Balance Volume indicators, and a bullish Relative Strength Index.

He also examined Grey Matters' performance relative to the CDNX index, identifying a formation that had developed from a bull wedge into a rectangular base pattern, with the Stochastics indicator showing a "Buy" signal.

The analyst separately reviewed the broader healthcare sector, identifying a ten-year uptrend in a U.S. healthcare sector exchange-traded fund. His observations included increased trading volume during rallies, supportive moving averages, a Stochastics buy signal, and money-flow indicators he characterized as bullish.

Thomson's fundamental discussion addressed Grey Matters' planned Davie clinic opening, its relationship with Catalyst MedTech, the non-binding letter of intent involving at least 200 clinical-trial scans at a potential second Florida location, and its longer-term national expansion plans.

He also identified the two approved Alzheimer's antibody treatments as a source of demand for amyloid testing, while noting approximately 158 Alzheimer's drug candidates undergoing clinical evaluation at the time of his report.

The analysis acknowledged risks associated with financing, potential shareholder dilution, operational execution and dependence on the CareMiBrain technology and related commercial arrangements. 

Ownership and Share Structure2

Institutions hold about 59.90% of Grey Matters, while management and insiders own approximately 19.00%, with retail investors accounting for the balance.

The largest disclosed holders are AlphaNorth Asset Management (18.00%) and Christopher Moreau (6.05%).

Grey Matters has roughly 11.29 million shares outstanding and a market capitalization of about CA$4.0 million.

Insiders were buyers over the last six months, purchasing about 555,000 shares, with no verified open-market sales in that window.

Seven series of warrants remain outstanding. Public records show two historical share restructures.


Want to be the first to know about interesting Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. Subscribe

Important Disclosures:

  1. Grey Matters Health Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship. 
  2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health Inc. 
  3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
  4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
  5. This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on September 10, 2026

  1. Grey Matters Health Inc.  has paid Street Smart (an affiliate of Streetwise Reports) a fee of US$3,000 for the preparation of an independent technical research report, published on September 10, 2026.
  2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. Mr. Thomson is not an investment advisor. He does not know the financial situation or risk tolerance of any reader. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed. Mr. Thomson owns no securities in Grey Matters Health Inc., and he has no direct financial relationship with the company.

2. Ownership and Share Structure Information

Ownership percentages, named holders, share count, market capitalization, and the 52-week range for Grey Matters were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-02 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-02 and excludes option exercises. These are public-source estimates and can differ from a later official register.





Want to read more about Healthcare Services investment ideas?
Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe